Aridis Pharmaceuticals Future Growth

Future criteria checks 0/6

Aridis Pharmaceuticals's revenue and earnings are forecast to decline at 72.1% and 130.7% per annum respectively while EPS is expected to decline by 117.5% per annum.

Key information

-130.7%

Earnings growth rate

-117.5%

EPS growth rate

Biotechs earnings growth	24.0%
Revenue growth rate	-72.1%
Future return on equity	n/a
Analyst coverage	Low
Last updated	06 Nov 2023

Recent future growth updates

Recent updates

Aridis Pharmaceuticals announces proposed public stock offering; shares down ~30%

Sep 26

Aridis Pharmaceuticals GAAP EPS of -$0.45, revenue of $0.29M

Aug 16

Can You Imagine How Aridis Pharmaceuticals' (NASDAQ:ARDS) Shareholders Feel About The 32% Share Price Increase?

Feb 17

Aridis Pharmaceuticals EPS misses by $0.02

Nov 20

Aridis Pharmaceuticals (ARDS) Investor Presentation - Slideshow

Oct 31

Earnings and Revenue Growth Forecasts

OTCPK:ARDS - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2024	8	-4	N/A	N/A	1
12/31/2023	21	4	N/A	N/A	1
9/30/2023	22	-1	-18	-18	N/A
6/30/2023	22	-9	-21	-21	N/A
3/31/2023	3	-29	-23	-23	N/A
12/31/2022	3	-30	-29	-29	N/A
9/30/2022	3	-33	-24	-24	N/A
6/30/2022	3	-49	-29	-29	N/A
3/31/2022	3	-46	-29	-29	N/A
12/31/2021	2	-46	-23	-23	N/A
9/30/2021	1	-43	-25	-24	N/A
6/30/2021	0	-25	-22	-21	N/A
3/31/2021	1	-24	-21	-20	N/A
12/31/2020	1	-22	-21	-20	N/A
9/30/2020	1	-22	-12	-12	N/A
6/30/2020	1	-24	-2	-2	N/A
3/31/2020	N/A	-28	-5	-5	N/A
12/31/2019	1	-30	-8	-8	N/A
9/30/2019	2	-29	-21	-21	N/A
6/30/2019	3	-30	-29	-29	N/A
3/31/2019	3	-23	-28	-28	N/A
12/31/2018	3	-23	-25	-24	N/A
9/30/2018	2	-24	-21	-20	N/A
6/30/2018	1	-22	-21	-19	N/A
3/31/2018	1	-27	-20	-19	N/A
12/31/2017	1	-27	-18	-18	N/A
9/30/2017	0	-26	-16	-16	N/A
12/31/2016	2	-9	N/A	-6	N/A
12/31/2015	3	-8	N/A	-4	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: ARDS is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: ARDS is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: ARDS is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: ARDS's revenue is expected to decline over the next 3 years (-72.1% per year).

High Growth Revenue: ARDS's revenue is forecast to decline over the next 3 years (-72.1% per year).

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if ARDS's Return on Equity is forecast to be high in 3 years time

Aridis Pharmaceuticals Future Growth

Future criteria checks 0/6

Key information

Recent future growth updates

Price target decreased by 43% to US$6.00

No longer forecast to breakeven

Price target decreased to US$9.67

No longer forecast to breakeven

No longer forecast to breakeven

Consensus revenue estimates fall by 20%

Recent updates

Aridis Pharmaceuticals, Inc., Annual General Meeting, Dec 15, 2023

Nasdaq To File A Form 25 with the Securities and Exchange Commission to Complete the Delisting Common Stock of Aridis Pharmaceuticals

Aridis Pharmaceuticals Common Stock to Delist from Nasdaq Capital Market on July 19

Aridis’ AR-301 Monoclonal Antibody is Among the First Biologics to Receive FDA’s Qualified Infectious Diseases Product (QIDP) Designation

Aridis Pharmaceuticals, Inc. Receives Agreement from the FDA on a Single Confirmatory Phase 3 Study of AR-301 and the Clinical Study Design

Aridis Pharmaceuticals Receives Nasdaq Notice on Late Filing of its Form 10-Q

Aridis Pharmaceuticals, Inc. announced delayed 10-Q filing

Price target decreased by 43% to US$6.00

Insufficient new directors

Aridis Pharmaceuticals, Inc. Announces Top-Line Results from the AR-301-002 Phase 3 Study

Aridis Pharmaceuticals, Inc. Announces New Approaches to Treating Infections in Cystic Fibrosis Patients - AR 501 Phase 2 Trial Update

Aridis Pharmaceuticals, Inc. announced that it has received $4.848271 million in funding from Cystic Fibrosis Foundation

Aridis Announces A Key Milestone of Closing of Patient Enrollment in the Phase 2A Study of AR-501 in Cystic Fibrosis Patients

Aridis Pharmaceuticals, Inc. announced delayed 10-Q filing

Insufficient new directors

Aridis Pharmaceuticals, Inc. announced that it has received $8 million in funding

Aridis Pharmaceuticals Receives Non-Compliance Letter from Nasdaq

Aridis Announces the Closing of Patient Enrollment in the AR-301 Global Phase 3 Superiority Study

Aridis Pharmaceuticals announces proposed public stock offering; shares down ~30%

Aridis Pharmaceuticals, Inc. announced delayed 10-Q filing

No longer forecast to breakeven

Aridis Pharmaceuticals GAAP EPS of -$0.45, revenue of $0.29M

Aridis Pharmaceuticals, Inc. Announces its Inhaled Treatment of its Fully Human Monoclonal Antibody Cocktail AR-701 Resulted in No Detectable SARS-CoV-2 Virus in the Lungs of Infected Rhesus Macaques, and Protected Their Lungs from Disease

Insufficient new directors

Insufficient new directors

Price target decreased to US$9.67

No longer forecast to breakeven

Aridis Pharmaceuticals, Inc., Annual General Meeting, Jun 02, 2022

Aridis Pharmaceuticals Receives Written Notification from the Listing Qualifications Department of the Nasdaq Stock Market LLC Regarding Minimum Market Value Requirement

Aridis Pharmaceuticals, Inc. announced delayed annual 10-K filing

Aridis Pharmaceuticals, Inc. Provides Update on its Pan-Coronavirus Monoclonal Antibody Cocktail AR-701 in COVID-19 Omicron Infected Animals

Aridis Pharmaceuticals, Inc. Receives Funding to Evaluate Inhaled Monoclonal Antibodies to Block Influenza and SARS-CoV-2 Transmission

No longer forecast to breakeven

Aridis Pharmaceuticals Announces a Pan-Coronavirus Monoclonal Antibody Cocktail That Retains Effectiveness Against the Omicron variant, other COVID-19 Variants, SARS, MERS, and the Common Cold Human Coronaviruses

Consensus revenue estimates fall by 20%

Price target decreased to US$15.00

Price target increased to US$19.00

Aridis Pharmaceuticals, Inc. Announces Covid mAb AR-712 Neutralizes SARS-CoV-2 Delta Variant

Chief Financial Officer Michael Nazak has left the company

Consensus forecasts updated

Consensus forecasts updated

Aridis Pharmaceuticals, Inc. Enters into Out-Licensing and Product Discovery Agreement with Kermode Biotechnologies, Inc

Aridis Pharmaceuticals Provides Multiple Program Updates Including the Addition of A Second Inhaled Antibody to Neutralize Newly Emerging Covid-19 Mutated Variants

Can You Imagine How Aridis Pharmaceuticals' (NASDAQ:ARDS) Shareholders Feel About The 32% Share Price Increase?

New 90-day high: US$8.08

Aridis Pharmaceuticals EPS misses by $0.02

Aridis Pharmaceuticals, Inc. announced delayed 10-Q filing

Aridis Pharmaceuticals (ARDS) Investor Presentation - Slideshow

New 90-day low: US$6.38

New 90-day high: US$8.01

Aridis Pharmaceuticals, Inc. to Present At the H.C. Wainwright 21 Annual Global Investment Conference on September 10, 2019

Analysts increase revenue estimates to US$1.63m

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies